American Association for the Advancement of Science
Up to 30 percent of patients with B cell malignancies such as lymphoma relapse after CAR T cell treatment, partly because their lymphoma cells stop expressing the target antigen
NeuroD1-based gene therapy could potentially be used to treat stroke, which is a leading cause of disability in the US, with 800,000 new stroke patients every year
We’ve updated our Privacy Policy to make it clearer how we use your personal data. Please read our Cookie Policy to learn how we use cookies to provide you with a better experience.